T
Tito R. Mendoza
Researcher at University of Texas MD Anderson Cancer Center
Publications - 288
Citations - 20415
Tito R. Mendoza is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Cancer pain. The author has an hindex of 62, co-authored 263 publications receiving 17679 citations. Previous affiliations of Tito R. Mendoza include University of Wisconsin-Madison & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
A New Measure Of Symptom Burden In Chronic Graft-Versus-Host Disease
Loretta A. Williams,Daniel R. Couriel,Tito R. Mendoza,P.L. McCarthy,Joyce Neumann,M.H. White,Gary M. Mobley,S. Kapoor,L.K. Hernandez,Amin M. Alousi,Charles S. Cleeland +10 more
Journal ArticleDOI
Percutaneous Cordotomy for Pain Palliation in Advanced Cancer: A Randomized Clinical Trial Study Protocol.
Ashwin Viswanathan,Aditya Vedantam,Loretta A. Williams,Dhanalakshmi Koyyalagunta,Salahadin Abdi,Patrick M. Dougherty,Tito R. Mendoza,Roland L. Bassett,Ping Hou,Eduardo Bruera +9 more
TL;DR: This randomized clinical trial comparing cordotomy with a control intervention will provide the level of evidence necessary to determine whether cordotomy should be the standard of care intervention for patients with advanced cancer pain.
Journal ArticleDOI
Validation study of the Arabic version of the Brief Fatigue Inventory (BFI-A).
Khaled Suleiman,Mahmoud Al Kalaldeh,Loai Abu-Sharour,Bernice C. Yates,Ann M. Berger,Tito R. Mendoza,Malakeh Z. Malak,Ayman Bani Salameh,Charles S. Cleeland,Ahmed Menshawi +9 more
TL;DR: This study suggests that the BFI-A is a reliable and valid tool to assess fatigue among Arab cancer patients.
Journal ArticleDOI
Concept domain validation and item generation for the Treatment-Induced Neuropathy Assessment Scale (TNAS)
TL;DR: The TNAS, developed with direct patient input, provides an easily administered and conceptually valid method of patient report of TIPN burden for use in research and practice.
Journal ArticleDOI
Patient-reported fatigue in head and neck cancer survivors.
Gary Brandon Gunn,Tito R. Mendoza,Adam S. Garden,X. S. Wang,William H. Morrison,S.J. Frank,Ehab Y. Hanna,Charles Lu,Beth M. Beadle,Kian K. Ang,Charles S. Cleeland,David I. Rosenthal +11 more
TL;DR: Overall, 10% of patients have MS persistent fatigue well after completing treatment with RT or CRT for HNC, and a phase II trial investigating a CNS stimulant in reducing patient-reported fatigue is planned.